These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9855318)

  • 1. Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus.
    Piscitelli SC; Vogel S; Figg WD; Raje S; Forrest A; Metcalf JA; Baseler M; Falloon J
    Pharmacotherapy; 1998; 18(6):1212-6. PubMed ID: 9855318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.
    Hennessy M; Clarke S; Spiers JP; Mulcahy F; Kelleher D; Meadon E; Maher B; Bergin C; Khoo S; Tjia J; Hoggard P; Back D; Barry M
    Antivir Ther; 2003 Jun; 8(3):191-8. PubMed ID: 12924535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
    Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR
    Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
    Murphy RL; Sommadossi JP; Lamson M; Hall DB; Myers M; Dusek A
    J Infect Dis; 1999 May; 179(5):1116-23. PubMed ID: 10191212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
    Hamzeh FM; Benson C; Gerber J; Currier J; McCrea J; Deutsch P; Ruan P; Wu H; Lee J; Flexner C;
    Clin Pharmacol Ther; 2003 Mar; 73(3):159-69. PubMed ID: 12621381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients.
    Piscitelli SC; Wells MJ; Metcalf JA; Baseler M; Stevens R; Davey RT
    Pharmacotherapy; 1996; 16(5):754-9. PubMed ID: 8888071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
    Brendel K; Legrand M; Taburet AM; Baron G; Goujard C; Mentré F;
    Fundam Clin Pharmacol; 2005 Jun; 19(3):373-83. PubMed ID: 15910662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
    Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection.
    Piscitelli SC; Forrest A; Vogel S; Chaitt D; Metcalf J; Stevens R; Baseler M; Davey RT; Kovacs JA
    Clin Pharmacol Ther; 1998 Nov; 64(5):492-8. PubMed ID: 9834041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
    Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
    J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: a multicenter, randomized, open-label, controlled, four-period crossover trial.
    Grases F; García-González R; Redondo E; Costa-Bauzá A; Simonet BM; Sartini RP; Bassa A; Gallegos C; Payeras A; Saro D; Martinez AI; Cifuentes C; Homar F; Murillo JA; Fernández C; Riera M; Conte A
    Clin Ther; 2004 Dec; 26(12):2045-55. PubMed ID: 15823768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus.
    Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.
    Levin GM; Nelson LA; DeVane CL; Preston SL; Eisele G; Carson SW
    Psychopharmacol Bull; 2001; 35(2):62-71. PubMed ID: 12397887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
    Pelton SI; Stanley K; Yogev R; Fletcher CV; McIntosh K; Wiznia A; Nachman S;
    Clin Infect Dis; 2005 Apr; 40(8):1181-7. PubMed ID: 15791520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL; Stalker D; Keirns J
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens.
    Dicenzo R; Luque A; Larppanichpoonphol P; Reichman R
    J Antimicrob Chemother; 2006 Aug; 58(2):393-400. PubMed ID: 16760191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection.
    Haas DW; Stone J; Clough LA; Johnson B; Spearman P; Harris VL; Nicotera J; Johnson RH; Raffanti S; Zhong L; Bergqwist P; Chamberlin S; Hoagland V; Ju WD
    Clin Pharmacol Ther; 2000 Oct; 68(4):367-74. PubMed ID: 11061576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.
    Cruciani M; Gatti G; Vaccher E; Di Gennaro G; Cinelli R; Bassetti M; Tirelli U; Bassetti D
    J Antimicrob Chemother; 2005 Apr; 55(4):546-9. PubMed ID: 15728147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
    Burger D; Boyd M; Duncombe C; Felderhof M; Mahanontharit A; Ruxrungtham K; Ubolyam S; Stek M; Cooper D; Lange J; Phanupak P; Reiss P
    J Antimicrob Chemother; 2003 May; 51(5):1231-8. PubMed ID: 12668574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.